Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results

21-02-2014 Business Wire HealthComments (0)


Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013. Q4 2013 Highlights and Recent Events Completed enrollment in COMET-1, the phase 3 study of cabozantinib versus prednisone with the primary endpoint of overall survival in patients with advanced metastatic castration-resistant prostate cancer (CRPC). The study reached its enrollment target of 960 patients in September 2013 and the e

Read more on Business Wire Health

Cyclopropanes, Organofluorides, Quinolines, Health Medical Pharma, Oncology, Exelixis, Prostate cancer, Medicine, Tyrosine kinase inhibitors, Cabozantinib

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top